Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has issued an update.
CR Sanjiu reported its unaudited financial results for the first half of 2025, showing a 4.99% increase in revenue to RMB 14.81 billion, but a significant drop in net profit by 24.31% to RMB 1.82 billion. Despite the revenue growth, the decline in net profit and earnings per share indicates challenges in maintaining profitability, which could impact investor confidence and market positioning.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd is a company based in China, primarily engaged in the pharmaceutical industry. It is a subsidiary of China Resources Pharmaceutical Group Limited and is listed on the Shenzhen Stock Exchange.
Average Trading Volume: 11,247,567
Technical Sentiment Signal: Hold
Current Market Cap: HK$33.05B
For an in-depth examination of 3320 stock, go to TipRanks’ Overview page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money